• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Pharmacology for GAD: Complex Choices

Pharmacology for GAD: Complex Choices

November 15, 2019
Randall Moore, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Randall Moore, MD. Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Slee A et al, Lancet 2019;393(10173):768–777


Study Type: Network meta-analysis


With over 2 dozen choices, how do we pick a medication for generalized anxiety disorder (GAD)? The authors of this network meta-analysis sought to answer this question.


Network meta-analysis allows researchers to gauge treatments that haven’t been directly compared in head-to-head studies. If drug A works better than drug B and B works better than C, then the network meta-analysis concludes that A is likely to work better than C, even though A and C have never been directly compared.


The investigators selected 89 trials of 25 drugs studied in over 25,000 patients. The primary outcome was change in the Hamilton Rating Scale for Anxiety (HAM-A). Trial length varied from 4 to 26 weeks.


Surprisingly, quetiapine XR was the most efficacious among the medications with large sample sizes. However, its benefit was modest, with a reduction of 3.6 points on the HAM-A compared to placebo (150–300 mg per night, as monotherapy). Quetiapine XR was poorly tolerated with a high discontinuation rate (odds ratio 1.44). The following drugs were well tolerated and are listed in order of efficacy: duloxetine, pregabalin, venlafaxine XR, and escitalopram.


The 4 benzodiazepines were studied as a class, not as individual drugs. Patients quit benzodiazepines much more often than placebo (odds ratio 1.43), although the reasons for discontinuation were not explored.


Studies were excluded if the patients had psychiatric comorbidities other than depression, which means the subjects might have been significantly less ill than the patients we see in routine practice.


One-third of the trials were not placebo controlled, and a fairly large number of them had limited quality. However, a sensitivity analysis concluded that these deficiencies did not significantly distort the results.


Although the meta-analysis did not analyze the data according to the quality of the studies, dose, or duration of treatment, TCPR has analyzed these issues by drilling down on the appendix and the original studies. The studies of pregabalin were all of lower quality. The studies of duloxetine were of the highest quality, followed by escitalopram and venlafaxine XR. For duloxetine, venlafaxine, and escitalopram, high doses (eg, duloxetine 120 mg) were no more efficacious than medium doses (eg, duloxetine 60 mg). Of these 3 antidepressants, only venlafaxine XR was studied for more than 12 weeks, and those studies demonstrated greater efficacy than shorter studies, suggesting that its benefits may build over time.


TCPR’S TAKE
In GAD, duloxetine stands out for its efficacy, safety, and the quality of its studies. This antidepressant has FDA approval in childhood GAD as well. It may take a few months to see the full effects of antidepressants in GAD, and medium doses are as likely to work as higher ones. Quetiapine XR is one of the more effective medications for GAD, but it has major safety and tolerability issues that caused the FDA to withhold its approval in 2009.



For an in-depth look at generalized anxiety disorder and its cousin, neuroticism, listen to our 4-part podcast series, premiering in November.


Search for “Carlat” on your podcast store.



 

General Psychiatry
KEYWORDS cymbalta duloxetine effexor generalized-anxiety-disorder lyrica pharmacology pregabalin research research-update ssris venlafaxine
Randall Moore, MD.

An Answer for Psychotic Depression

More from this author
www.thecarlatreport.com
Issue Date: November 15, 2019
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Adult ADHD, TCPR, November/December 2019
Highlights From This Issue
Adult-Onset ADHD
Micronutrients in Mental Health
Adult ADHD: What Else Could It Be?
Stimulants as Cognitive Enhancers
A Practical Guide to Light Therapy
Meet the First H3 Antagonist
An Antipsychotic Patch
Pharmacology for GAD: Complex Choices
Olanzapine for Anorexia Nervosa
In Brief: Antipsychotic Update
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • KellieElvis2.jpeg
    General Psychiatry

    Elvis Presley and Pharmacokinetics - Part 2

    This common pharmacokinetic reaction will help you manage many bad medication reactions in psychiatric practice. But did it lead to Elvis Presley’s death? 

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.